Overview
- 4 inspections across 4 sites are on record.
- 18 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2022-11-16.
At a glance
Inspections
4
Sites
4
Observations
18
Career since
May 2020
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| XERIS PHARMACEUTICALS INC | 16 Nov 2022 | Human Drugs | |
| Integrated Laboratory Systems LLC, An Inotiv Company | 30 Sep 2022 | Human Drugs | View 483 → |
| Labcorp Early Development Laboratories, Inc. | 12 Aug 2022 | Human Drugs | View 483 → |
| Alturas Analytics, Inc. | 5 May 2020 | Human Drugs | View 483 → |
Sites inspected
XERIS PHARMACEUTICALS INCChicago, United States1 insp.
Integrated Laboratory Systems LLC, An Inotiv CompanyMorrisville, United States1 insp.
Labcorp Early Development Laboratories, Inc.Greenfield, United States1 insp.
Alturas Analytics, Inc.Moscow, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Yangmin Ning1 shared
Jeanne J Thai1 shared
Corrine M Carter1 shared
Betsy C Galliher1 shared
Mark J Seaton1 shared
Sunitha K Rajaram1 shared
Angela Shepas1 shared
Full investigator report
Get the verbatim findings behind Lynda L Lanning's 18 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site